Regulus (RGLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Ram Selvaraju has given his Buy rating due to a combination of factors centering around Regulus Therapeutics’ recent developments with their product, RGLS8429, which is designed to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD). The rating is influenced by the positive exploratory results from their Phase 1b multiple-ascending dose study which indicated that RGLS8429 had a consistent impact on reducing height-adjusted total kidney volume (htTKV) across patients with high risks of kidney function decline. Additionally, the safety profile of RGLS8429 meets expectations, reinforcing the asset’s risk-mitigated status, and there is anticipation for further data reports and a potential end-of-Phase 1 meeting with the FDA in the near future.
Moreover, the drug demonstrated significant increases in urinary polycystin levels and a reduction in kidney volume in a substantial majority of patients in the latest cohort of the study, showcasing its tolerability and efficacy. The observed dose response and the inverse correlation between urinary polycystin levels and disease severity suggest that higher doses may lead to better patient outcomes. Selvaraju’s confidence in Regulus’s path forward, including a pivotal Phase 2 trial and possible accelerated approval, is further underpinned by these promising results. This comprehensive assessment of the drug’s performance and the company’s strategic direction underlies the Buy rating and the optimistic $10 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Regulus (RGLS) Company Description:
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpomqWuerOt06KloGWRm7Oqvsyem2aen6d6s7HGrqOuq12ptaa%2BwKmcrqyZmMBurcyim2aon6i2tbXVnmSrn5yohXV%2BmGaqra2UrnqzsdKuo62rXWZ9dH%2BUbnBsa2U%3D